Влияние фиксированной комбинированной терапии телмисартаном/амлодипином на кардиометаболические риски у пациентов с артериальной гипертензией

М Атоева; Г Абдуллаева; Г Хамидуллаева; С Бекметова; Х Юсупова; В Мансурова

doi:10.70626/cardiouz-2026-3-00086

Jild 3 № 2 (2026): Aprel - Iyun

43-54

2026-06-29

Ochiq kirish

Munisa I.Atoeva

Guzal Zh.Abdullaeva

Gulnoz A.Xamidullaeva

Sevara I.Bekmetova

Xafiza F.Yusupova

Vasila X.Mansurova

https://doi.org/10.70626/cardiouz-2026-3-00086

Qabul qilingan: 2026-06-17

Nashr etilgan: 2026-06-29

Annotatsiya

Tadqiqot maqsadi: arterial gipertenziyali (AG) bemorlarda telmisartan/amlodipin fiksirlangan kombinatsiyasi bilan 6 oylik terapiyaning antigipertenziv samaradorligini, kardiometabolik xavf omillariga ta'sirini, nishon organlar zararlanishining regressini va xavfsizligini baholash.

Material va usullar. Tadqiqotga ESH 2023 yil tasnifiga ko'ra I–II darajali AG bilan og'rigan 18–65 yoshli (o'rtacha yosh 51.90±13.84) 52 nafar bemor jalb qilindi. Barcha bemorlarga telmisartan/amlodipin fiksirlangan kombinatsiyasi tayinlandi. Tekshiruv boshlang'ich holatda va 6 oydan keyin o'tkazildi: ofisdagi AB (arterial bosim) o'lchandi, exokardiografiya, applanatsion tonometriya, uyqu arteriyalarining dupleks skanerlashi o'tkazildi, glyukoza, lipidlar, siydik kislotasi, jigar transaminazalari, kreatinin darajalari koptokchali filtratsiya tezligini (KFT) hisoblash bilan birga baholandi, ertalabki siydikda mikroalbuminuriya (MAU) aniqlandi.

Natijalar. Telmisartan/amlodipin fiksirlangan kombinatsiyasi bilan 6 oylik terapiyadan so'ng SAB (sistolik arterial bosim) 19.54% ga, DAB (diastolik arterial bosim) 16.67% ga pasaydi (p<0,001). Chap qorincha gipertrofiyasining (ChQG) sezilarli regressi qayd etildi, bu ChQMI (chap qorincha miokardi massasi indeksi)ning 7.6% ga kamayishi bilan baholandi. PTTT (puls to'lqinining tarqalish tezligi) statistik jihatdan ahamiyatli darajada 9.95±2.13 m/s dan 9.00±1.12 m/s gacha pasaydi (p=0.019). KFT oshdi. O'tkazilayotgan terapiya fonida lipid profili yaxshilandi (UX (umumiy xolesterin) darajasi (p=0.009) va PZLP-X (past zichlikdagi lipoproteidlar xolesterini) (p=0.018) pasaydi).

Xulosa. Telmisartan/amlodipin bilan fiksirlangan kombinatsiyali olti oylik terapiya yuqori antigipertenziv samaradorlikni, aniq kardio-, vazo- va nefroprotektsiyani, shuningdek AG bemorlarida metabolik profilga ijobiy ta'sirni namoyish etdi, bu uni, ayniqsa kardiometabolik xavf omillari mavjud bo'lganda, tanlov kombinatsiyasiga aylantiradi.

Kalit so‘zlar

Adabiyotlar ro'yxati

World Health Organization. Hypertension. WHO Fact Sheet. 2024. Available at: https://www.who.int/ news-room/fact-sheets/detail/hypertension.
World Health Organization Uzbekistan Health data overview for the Republic of Uzbekistan.https://data.who.int/countries/860.
Kario K, Okura A, Hoshide S, et al. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47(5):1099-1102. https://doi.org/10.1038/s41440-024-01622-w.
McEvoy JW, McCarthy C, Bruno JG, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. https://doi.org/10.1093/eurheartj/ehae1 78.
Rodgers A, Salam A, Schutte AE, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404(10462):1536-1546. https://doi.org/10.1016/S0140-6736(24)01744-6.
Elbardisy S, Alotaibi MN, Saad AR, et al. Single-Pill Combination Therapy of Amlodipine, Telmisartan, and Chlorthalidone in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials. Cureus. 2024;16(9):e68802. https://doi.org/10.7759/cureus.68802.
Morawietz H, Bornstein SR. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;170:115996. https://doi.org/10.1016/j.biopha.2023.115996.
The ONTARGET Investigators Telmisartan, Ramipril Both in Patients at High Risk Vascular Events N Engl О Med 2008;358:1547-1559.
Cho EJ, Kim MH, Kim YH, et al. Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. J Clin Hypertens (Greenwich). 2023;25(9):817-827. https://doi.org/10.1111/jch.14707.
Sung KC, Sung JH, Cho EJ, et al. Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. J Clin Hypertens (Greenwich). 2022;24(10):1298-1309. https://doi.org/10.1111/jch.14570.
Kim HM, Hwang IC, Choi HM, et al. Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension. Front Cardiovasc Med. 2022;9:1082008. https://doi.org/10.3389/fcvm.2022.1082008.
Martin TG, Juarros MA, Leinwand LA. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat Rev Cardiol. 2023;20(5):347-363. https://doi.org/10.1038/s4 1569-022-00806-6.
Kawasoe S, Ohishi M. Regression of left ventricular hypertrophy. Hypertens Res. 2024;47(3):627-639. https://doi.org/10.1038/s41440-024-01634-6.
Spronck B, Terentes-Printzios D, Avolio AP, et al. 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices. Hypertension. 2024;81(1):183-192. https://doi.org/10.1161/HYPERTENSIONAHA.123.21618.
An DW, Hansen TW, Aparicio LS, et al. Derivation of an Outcome-Driven Threshold for Aortic Pulse Wave Velocity: An Individual-Participant Meta-Analysis. Hypertension. 2023;80(12):1949-1959. https://doi.org/10.1161/HYPERTENSIONAHA.123.21318.
Vasan RS, Pan S, Xanthakis V, et al. Arterial Stiffness and Long-Term Risk of Health Outcomes: The Framingham Heart Study. Hypertension. 2022;79(5):1045-1056. https://doi.org/10.1161/HYPERTENSIONAHA.121.18776.
Park S, Hwang D, Kang J, et al. Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients with Dyslipidemia and Hypertension: A Multicenter Randomized Clinical Trial. Curr Ther Res Clin Exp. 2024;100:100735. https://doi.org/10.1016/j.curtheres. 2024.100735.
Habboush S, Kagita NV, Gadelmawla AF, et al. Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-Analysis. High Blood Press Cardiovasc Prev. 2024;32(1):49-60. https://doi.org/10.1007/s40292-024-00689-3.